Search Results
Your search for ,wAS matches 28044 pages
Showing 19801 - 19850ASCO Releases the Updated Version of Its Value Framework
Last June, ASCO published its initial concept for a value framework in the Journal of Clinical Oncology (JCO).1 The framework, developed by ASCO’s Value in Cancer Care Task Force, is designed to provide a standardized approach to assist physicians and patients in assessing the “value” of a new...
Expert Point of View: Dominique Valteau-Couanet, MD, PhD
Study discussant Dominique Valteau-Couanet, MD, PhD, of the Gustave Roussy in France, said the study was “an important step” in research, by showing “Cy-THIO/mCEM [tandem autologous stem cell transplant (ASCT) with cyclophosphamide/thiotepa followed by a modified regimen of...
For High-Risk Neuroblastoma, Two Transplants May Be Better Than One
In children with high-risk neuroblastoma, tandem autologous stem cell transplant (ASCT) improved event-free survival rates in the ANBL0532 trial from the Children’s Oncology Group. The study was presented at the plenary session of the 2016 ASCO Annual Meeting by Julie R. Park, MD, of Seattle...
Autologous Stem Cell Transplantation Offers Safe, Effective Option for Patients With HIV-Associated Lymphoma
A phase II, multicenter trial published by Alvarnas et al in Blood challenges the generally held belief that individuals with human immunodeficiency virus (HIV) and aggressive lymphoma are not candidates for standard treatment. According to the researchers, people with HIV-associated lymphoma who...
Is Anti–PD-L1 Antibody Durvalumab Active in Advanced Urothelial Bladder Cancer?
In a phase I/II study reported in the Journal of Clinical Oncology, Massard et al found that the anti–PD-L1 (programmed cell death ligand 1) antibody durvalumab was active in patients with previously treated advanced urothelial bladder cancer. Objective response appeared to be confined to...
Low-Dose CT Screening May Detect New Solid Nodules and Lung Cancer Probability
As reported by Walter et al in The Lancet Oncology, incidence screening with low-dose computed tomography (CT) in high-risk individuals detected new solid nodules in approximately 5% to 7% at second and third screenings in the ongoing Dutch-Belgian NELSON trial. Larger nodule size was associated...
Final Results of METEOR Trial Show Cabozantinib Improves Overall Survival vs Everolimus in Advanced RCC
As reported by Choueiri et al in The Lancet Oncology, the final results of the phase III METEOR trial indicate significantly improved overall survival with cabozantinib (Cabometyx) vs everolimus (Afinitor) in patients with advanced renal cell carcinoma (RCC) that had progressed after previous...
Genomic Classification and Outcome in Acute Myeloid Leukemia
As reported in The New England Journal of Medicine, Papaemmanuil et al have identified 11 genomic subgroups in acute myeloid leukemia (AML) associated with distinct diagnostic features and clinical outcomes. AML Subgroups The study included analysis of driver mutations in 111 cancer genes and...
Improved Quality of Life Reported With Nivolumab vs Everolimus in Advanced Renal Cell Carcinoma
Patients with previously treated advanced renal cell carcinoma receiving nivolumab (Opdivo) in the phase III CheckMate 025 trial had improved health-related quality of life compared with those receiving everolimus (Afinitor), as reported by Cella et al in The Lancet Oncology. Study Details In the ...
SNMMI 2016: VASH Collimator Allows Three-Dimensional Imaging of the Breast With Less Radiation
Preliminary tests have demonstrated that a new device may enable existing breast cancer imagers to provide up to six times better contrast of tumors in the breast, while maintaining the same or better image quality and halving the radiation dose to patients. The advance is made possible by a new...
Protein Could Help Identify Chronic Graft-vs-Host Disease
A new study published by Kariminia et al in the journal Blood has identified a protein that could diagnose chronic graft-vs-host disease in patients undergoing blood and bone marrow transplantation. The work was led by researchers in the Michael Cuccione Childhood Cancer Research Program at BC...
Japanese Trial Shows Improved Survival With Adjuvant S-1 vs Gemcitabine in Resected Pancreatic Cancer
Updated results of a Japanese phase III trial (JASPAC 01) reported in The Lancet by Uesaka et al showed that adjuvant S-1 was associated with significantly better overall survival compared with gemcitabine in patients with resected pancreatic cancer. Study Details In the open-label noninferiority ...
SNMMI 2016: Pretargeted Radioimmunotherapy Eliminates Colorectal Cancer in Preclinical Studies
Presenters at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) unveiled a novel radioimmunotherapy that combines a cancer-seeking antibody with potent radionuclide agents, resulting in complete remission of colorectal cancer in mouse models (Scientific Paper...
SNMMI 2016: Personalized Kidney Dosimetry Optimizes Radiotherapy Dose in Patients With Neuroendocrine Tumors
Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) presented a molecular imaging technique that allows oncologists to set patients’ radiotherapy doses right at that critical limit of delivering the most powerful dosage to neuroendocrine...
Lifestyle Pattern May Be Associated With Cancer Risk in White Adults
In a study reported in JAMA Oncology, Song and Giovannucci found that a “healthy lifestyle pattern” was associated with a reduced risk for carcinomas among white adults. Study Details The study included data from the Nurses’ Health Study and the Health Professionals Follow-up...
Study Finds Inotuzumab Ozogamicin Improves Outcomes vs Standard Therapy in Relapsed/Refractory ALL
In a phase III trial reported in The New England Journal of Medicine, Kantarjian et al found that treatment with the antibody-drug conjugate inotuzumab ozogamicin resulted in a greater complete remission rate and improved overall survival vs standard therapy in patients with relapsed/refractory...
Neoadjuvant Chemotherapy May Render Advanced Ovarian Cancers Responsive to Immunotherapy
Although most patients with advanced ovarian cancer initially respond to platinum-based chemotherapy, they usually relapse. According to a study by Böhm et al published in Clinical Cancer Research, neoadjuvant chemotherapy seemed to alter the immune cells in the tumors of patients with...
SNMMI 2016: A Blood-Based Multi-Transcript Test May Predict Success of Neuroendocrine Cancer Therapy
Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor long-term survival. According to research presented at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an investigative blood test could...
SNMMI 2016: FDG-PET Evaluates Immunotherapy for Non–Small Cell Lung Cancer
Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) presented a means of evaluating an immunotherapy that fights off non–small cell lung cancer (NSCLC) by strengthening a patient’s own immune system (Scientific Paper 134). Due to...
Mindfulness-Based Stress-Reduction Program May Reduce Psychological and Physical Symptoms in Breast Cancer Survivors
A mindfulness-based stress-reduction program for breast cancer survivors was associated with psychological and physical symptom benefits during and at 6 weeks after intervention, according to a randomized trial reported in the Journal of Clinical Oncology by Lengacher et al. Study Details In the...
Study Finds Pembrolizumab Active in Advanced Head and Neck Cancer
As reported by Seiwert et al in The Lancet Oncology, the monoclonal antibody pembrolizumab (Keytruda) showed activity in patients with programmed cell death ligand 1 (PD-L1)–positive recurrent or metastatic squamous cell carcinoma of the head and neck in the phase Ib KEYNOTE-012 study. Study ...
Adjuvant Chemotherapy in Early-Stage Non–Small Cell Lung Cancer Improves Overall Survival
The use of adjuvant chemotherapy in early-stage non–small cell lung cancer (NSCLC) patients improves overall survival and 5-year overall survival rates in patients with tumor sizes ranging from 3 to 7 cm. These findings were published by Morgensztern et al in the Journal of Thoracic...
Norwegian Study Shows Benefit of Aspirin as Secondary Prevention in Patients With Colorectal Cancer
A Norwegian population-based study reported in the Journal of Clinical Oncology by Bains et al showed that use of aspirin after diagnosis of colorectal cancer was associated with improved colorectal cancer–specific survival. Study Details In the population-based retrospective cohort study,...
ASCO 2016: Nivolumab Shows Promise in Refractory, Metastatic Anal Cancer
In the first-ever clinical trial for metastatic patients previously treated for the disease, research led by The University of Texas MD Anderson Cancer Center found that the immune checkpoint inhibitor nivolumab (Opdivo) shows promise for the majority of patients with squamous cell carcinoma of the ...
ASCO Releases Clinical Practice Guideline on Metastatic Pancreatic Cancer
As reported in the Journal of Clinical Oncology by Davendra P. Sohal, MD, MPH, of Cleveland Clinic, and colleagues, ASCO has released a clinical practice guideline on the treatment of patients with metastatic pancreatic cancer. Recommendations are based on expert panel systematic review of the...
ASCO Releases Clinical Practice Guideline on Treatment of Locally Advanced, Unresectable Pancreatic Cancer
As reported by Edward P. Balaban, DO, of Penn State Hershey Cancer Institute, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline on the treatment of locally advanced, unresectable pancreatic cancer. The recommendations are based on expert panel...
ASCO Releases Clinical Practice Guideline on Treatment of Potentially Curable Pancreatic Cancer
ASCO has released a clinical practice guideline on the treatment of potentially curable pancreatic cancer, as reported by Alok A. Khorana, MD, of Cleveland Clinic, and colleagues, in the Journal of Clinical Oncology. The recommendations are based on expert panel systematic review of the literature...
Increased Risk for Cardiovascular Events Seen in Patients With CML Taking Tyrosine Kinase Inhibitors
Although tyrosine kinase inhibitors have dramatically increased survival for patients with chronic myeloid leukemia (CML), continuous administration of these drugs may elicit long-term toxicity, including cardiovascular adverse events. To investigate the incidence of vascular events in patients...
European Study Suggests No Benefit of GnRH in Preserving Ovarian Function and Fertility in Young Women With Lymphoma
In long-term follow-up of a European trial reported by Demeestere et al in the Journal of Clinical Oncology, gonadotropin-releasing hormone (GnRH) agonist treatment during chemotherapy in young women with lymphoma was not associated with reduced premature ovarian failure or an improved pregnancy...
ASCO 2016: Nivolumab Extends Survival for Patients With Advanced Renal Cell Carcinoma Treated Beyond Disease Progression
In a large randomized study, the immunotherapy drug nivolumab (Opdivo), an anti–PD-1 (programmed cell death protein 1) monoclonal antibody, was shown to be a safe and effective therapy for kidney cancer even in patients who continued treatment after their disease progressed. Results ...
Study Finds Poor Understanding of Illness in Patients With Advanced Cancer
Few patients with advanced cancer and a short life expectancy have an accurate understanding of their illness, according to a study reported in the Journal of Clinical Oncology by Epstein et al. Study Details The study involved 178 patients from 9 U.S. cancer centers who had advanced cancers...
ASCO 2016: Cancer Diagnosed More Often in Patients With Primary Immunodeficiency Disease
Primary immunodeficiency disorders are a group of more than 300 single gene defects that affect the role of the immune system and prevent it from functioning properly. When Roswell Park Cancer Institute (RPCI) researchers evaluated the overall and site-specific incidence of cancer among patients...
FDA Approves EGFR Mutation–Detecting Blood Test for NSCLC
The U.S. Food and Drug Administration (FDA) recently approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the epidermal growth factor receptor (EGFR) inhibitor erlotinib (Tarceva). This is the first FDA-approved, blood-based genetic test that can detect EGFR gene...
International Prognostic Index for Chronic Lymphocytic Leukemia
The International Chronic Lymphocytic Leukemia–International Prognostic Index (CLL-IPI) working group has developed an International Prognostic Index for patients with chronic lymphocytic leukemia based on a meta-analysis of individual patient data, as reported in The Lancet Oncology. The...
Early Lapatinib-Related Rash in Breast Cancer
An analysis of the phase III adjuvant ALTTO trial showed that early rash was associated with better clinical outcome with lapatinib (Tykerb) treatment of HER2-positive breast cancer, as reported by Sonnenblick et al. It had been previously found that early rash was associated with improved...
ASCO Value in Cancer Care Task Force
The Value in Cancer Care Task Force was established in 2007 to educate oncologists about the importance of discussing costs associated with recommended treatments, empower patients to ask questions about the anticipated costs of their treatment options, identify the drivers of the rising costs of...
ASCO Updates Value in Cancer Care Framework
On May 31, 2016, ASCO published an updated framework for assessing the relative value of cancer therapies that have been compared in clinical trials. The framework, published by Schnipper et al,1 defines value as a combination of clinical benefit, side effects, and improvement in patient symptoms...
Philip A. Salem, MD, Honored by President of Mexico for Cancer Care
Oncologist Philip A. Salem MD, Director Emeritus of Cancer Research at Baylor St. Luke’s Medical Center in Houston, was honored as a physician and author on April 28 by the President of Mexico Enrique Peña Nieto and his government for Dr. Salem’s lifelong commitment to cancer care worldwide. Dr....
AUA Honors Its 2016 Annual Award Winners
The American Urological Association (AUA) honored its 2016 AUA award recipients during its 111th Annual Meeting in San Diego, Calfornia. These physician researchers, educators, and organizations were honored for their contributions to the field of medicine, the specialty of urology, and the AUA....
Cheryl Taylore Lee, MD, Named Urology Chair at The Ohio State University Wexner Medical Center
The Ohio State University Wexner Medical Center has named a prominent expert in bladder cancer, Cheryl Taylore Lee, MD, to lead its urology, uro/gynecology, and uro/oncologic programs, beginning July 1, pending approval by The Ohio State University Board of Trustees. Dr. Lee will be Chair of the...
The Importance of Listening to Patients
My experience with cancer, or more accurately, cancers, is complicated. In 2002, after returning from a medical mission to Honduras, I noticed a bean-sized lymph node above my left clavicle. As an oncology-certified nurse, I knew not to ignore any unusual nodules that pop up on the body and asked...
Rising
There were once two patients with leukemia. Other than their diagnoses and their ages, these two men had nothing in common. Meet Michael Michael was an artist—a sculptor. He had large, sensitive, blue eyes and a quiet, pensive manner. His acute observational power led him to ponder deep questions...
An Unusual Memoir of Cancer
“A book about the future must be written in advance. Later I won’t have the energy. So I will do it now.” So begins The Iceberg, a memoir set in Britain of a woman, Marion Coutts, whose husband was diagnosed with a brain tumor, which eventually killed him. Unfortunately, cancer memoirs flood the...
University of Maryland Greenebaum Cancer Center Designated as NCI Comprehensive Cancer Center
The University of Maryland Marlene and Stewart Greenebaum Cancer Center has been awarded the National Cancer Institute’s (NCI’s) highest designation as a Comprehensive Cancer Center. The prestigious distinction recognizes the cancer center’s high caliber of scientific leadership and robust programs ...
The Best HCAHPS Score: A Rodeo Invitation
An otherwise healthy, actively working, independent 60-year-old patient came to us with a several months’ history of abdominal pain. He had been seen by other physicians prior to coming to us for a second opinion. Our workup revealed a large cystic lesion emanating from the pancreas but involving ...
Low-Dose Chemical Exposure and Cancer
According to estimates from the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC), environmental toxic exposures are responsible for between 7% and 19% of human cancers. However, the 2008–2009 President’s Cancer Panel Annual Report estimated that the “true...
Increased Survival and Toxicity With Docetaxel, No Benefit of Zoledronic Acid, When Added to First-Line Hormone Therapy in Prostate Cancer
As reported in The Lancet by Nicholas D. James, BSc, MBBS, PhD, of the University of Warwick, and colleagues, survival results of the STAMPEDE trial, which used a multiarm, multistage seamless phase II/III design, provide little evidence of benefit of zoledronic acid and showed increased survival ...
SIRIUS Trial Heralds a New Era of Promise in Treating Resistant Myeloma
Multiple myeloma cells uniformly overexpress CD38.1 Daratumumab (Darzalex), a CD38-targeting human IgG1 kappa monoclonal antibody, has been evaluated in a series of phase I/II trials involving patients with relapsed or relapsed and refractory myeloma who have received at least two or more prior...
Daratumumab Shows High Activity in Heavily Pretreated and Refractory Multiple Myeloma
In the phase II SIRIUS trial reported in The Lancet, Sagar Lonial, MD, of Winship Cancer Institute, Emory University, and colleagues found that the CD38-targeted monoclonal antibody daratumumab (Darzalex) produced durable responses in patients with multiple myeloma who had received at least three ...
American Cancer Society Report Assesses Progress Against Goals Set for Nation 25 Years Ago
A new report assesses how the nation fared against the ambitious goal set by the American Cancer Society (ACS) to reduce cancer death rates by 50% over 25 years ending in 2015. The report finds areas where progress was substantial, and others where it was not. Published by Byers et al,1 the report ...
